Yoren Heart Launches Next-Generation Long-Term Ventricular Assist Device EVA-Pulsar™

The issue of heart failure is the leading health killer among Chinese people. According to authoritative research statistics, the number of heart failure patients in China exceeds 12 million and is showing an explosive growth trend, with an estimated 1 million severe heart failure patients. After receiving traditional drug treatments, the six-month mortality rate for severe heart failure can be as high as 60% to 80%, and the one-year survival rate is only 25%. The only hope for patients to extend their lives isHeart Transplant, but due to the scarcity of cardiac donors, only about 700 surgeries can be performed in a year. This is a drop in the bucket relative to China's庞大的 patient population, leaving the majority of patients and families陷入绝望. Therefore, severe heart failure has long been considered an incurable and绝望的 disease.

"Artificial Heart"It is currently the only option to address the scarcity of heart donors, effectively alleviating heart failure symptoms and helping patients regain their ability to live and work. The full name of the "artificial heart""Implantable Left Ventricular Assist Device", known as "the jewel in the crown of medical devices." Compared with heart transplant surgery, "artificial heart" has lower risks and better effects. On one hand, after the artificial heart is implanted, the patient's life expectancy is longer than drug treatment, and the long-term survival rate is equal to that of a heart transplant; on the other hand, there is no risk of organ rejection with an artificial heart, and there is an opportunity for a second upgrade.

EVAHEART Launches New Generation of Ultra-SmallEVA-Pulsar™The blood pump (EVAHEART, the first artificial heart in China approved for both short-term and long-term treatment with dual indications) has not only undergone improvements and upgrades in system and design but also significantly reduced its size while retaining advantages such as ultra-high flow and pulsatile blood flow, introducing revolutionary new features. Currently, in China, there are only...EVAHEART Self-DevelopedEVAHEART 1 andEVA-Pulsar™Approved for long-term use. The number of heart donors in China far fails to meet the demand of patients with end-stage heart failure.Artificial hearts require no waiting, have no risk of rejection, and their clinical needs and advantages are internationally recognized, allowing patients with severe heart failure to regain a beating "Chinese heart."

On March 27th (Tuesday) at 19:30, the 50th episode of VCBeat's "Artery Strict Selection New Product Review" invited Yan Hua, Director & CEO of EVAHEART, and Lin Wuyang, Senior Manager of EVAHEART's Marketing Department, to present their independently developed...New Generation Long-Term Artificial Heart Blood Pump EVA-Pulsar™Product Promotion.

Figure: EVAHEART's New Generation Artificial Heart Product

EVA-Pulsar™ Left Ventricular Assist Device

EVA-Pulsar™ adopts a new generation of open impeller technology, achievingFull Mainstream Design，Eliminate Secondary Flow Channel，The width at the narrowest point of the flow channel is 16mm., compared with the 1mm flow channel of HM3, there is a 16-fold improvement; compared with the secondary flow channels of other China-produced products, the improvement reaches 60 to 400 times.

Thanks to the optimization of the drive system and flow channel design of EVA-Pulsar™,The volume of Pulsar has been significantly reduced.，Its weight is260g，Only for EVAHEART first-generation products64%, but the maximum flow rate reaches 20L/min, which is twice that of other products on the market. Thanks to the open impeller and full-flow channel design, Pulsar's work efficiency has greatly improved. In daily use, a speed of about 1700RPM is sufficient to easily generate a blood flow of approximately 5L.

In the research and development of a new generation of ventricular assist devices, blood pulsatility has always been a key focus for breakthroughs. The EVA-Pulsar™ adaptive impeller and wide flow channel design bring a gentler HQ curve, allowing users' blood flow to generate a pulse pressure difference of 20-30mmHg.Maintain Blood Pulsatility, Reduce Various Complications。

EVA-Pulsar™, like the EVAHEART一代 blood pump, has been approved.Short-term adjuvant and long-term adjuvantTwo indications.

Scan the QR code on the poster to add the assistant and schedule a live broadcast.

Yan Hua

EVAHEART Director & CEO

Former Vice President of GE Healthcare (GE Healthcare) Greater China, and has served as Business General Manager, Investment and Strategy Director in several medical companies such as Johnson & Johnson Medical Devices, Boston Scientific, and Allegan.

Before joining the medical industry, Ms. Yan Hua worked at management consulting firms such as Mercer (Aon) and Deloitte, providing multi-industry clients in high-tech, aviation, energy, consumer goods, and other sectors with services in strategy, mergers and acquisitions, financial consulting, organizational restructuring, and more.

Ms. Hua Yan has work and life experiences in more than a dozen countries and regions around the world. In 2022, she was listed on the Fortune China's Most Influential Women in Business Future List.

Lin Wuyang

EVAHEART Senior Manager of Marketing Department

Successively held positions at Medtronic, Biotronik, Jiecheng Medical, and other high-tech medical device companies at home and abroad. Served in roles such as clinical technology, sales management, and marketing, with over 10 years of industry experience in the medical device sector.

Lin Wuyang graduated from Peking University with a double bachelor's degree in basic medicine and economics.

EVAHEART is a high-tech medical technology enterprise, a joint venture between China, Japan, and the United States, specializing in device-based treatments for heart failure. With its domestically produced "Implantable Left Ventricular Assist System" as a focal point, EVAHEART focuses on advanced innovative medical devices for severe heart failure treatment. The company develops and manufactures innovative medical device products across areas such as heart failure diagnosis, early prevention, intraoperative assistance, remote monitoring, ventricular assistance, and critical care diagnosis and treatment. EVAHEART provides comprehensive solutions for medical institutions and patients with severe heart failure.

The core product of EVAHEART is an implantable left ventricular assist device – the "EVAHEART" artificial heart. This product is currently the only artificial heart in China approved for long-term treatment and the only bionic artificial heart with a pulsatile blood flow.

EVAHEART, the artificial heart, was awarded the "2019 Major Progress in Chinese Medicine Certificate" by the Chinese Academy of Medical Sciences in January 2020. It was also selected as one of "China's Top Ten Scientific and Technological Achievements of 2019" by CCTV.com and has been widely used in developed regions such as Japan, Europe, and the United States, gaining official certification and consistent recognition from experts and scholars.

"Artery Strict Selection New Product Review" is a live broadcast column under "Artery Strict Selection" that supports the release of innovative medical products. The column's mission is: to assist in the milestone release of every medical innovation product.

Scan the QR code below to contact the assistant and schedule a live broadcast.

(If already added, please actively inquire with the assistant.)